Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis
Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/4/1241 |
id |
doaj-6820364fda3e4c8b82822b625b0816f3 |
---|---|
record_format |
Article |
spelling |
doaj-6820364fda3e4c8b82822b625b0816f32020-11-25T03:13:19ZengMDPI AGJournal of Clinical Medicine2077-03832020-04-0191241124110.3390/jcm9041241Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like FolliculitisTamara Quint0Patrick M. Brunner1Christoph Sinz2Irene Steiner3Robin Ristl4Kornelia Vigl5Susanne Kimeswenger6Katharina Neubauer7Detlev Pirkhammer8Martin Zikeli9Wolfram Hoetzenecker10Norbert Reider11Christine Bangert12Department of Dermatology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Dermatology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Dermatology, Medical University of Vienna, 1090 Vienna, AustriaInstitute of Medical Statistics, Medical University Vienna, 1090 Vienna, AustriaInstitute of Medical Statistics, Medical University Vienna, 1090 Vienna, AustriaDepartment of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, AustriaDepartment of Dermatology, Kepler University Hospital, 4020 Linz, AustriaDepartment of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Dermatology, Rudolfstiftung City Hospital, 1030 Vienna, AustriaDepartment of Dermatology, Wiener Neustadt Public Hospital, 2700 Wiener Neustadt, AustriaDepartment of Dermatology, Kepler University Hospital, 4020 Linz, AustriaDepartment of Dermatology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Dermatology, Medical University of Vienna, 1090 Vienna, AustriaDupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation.https://www.mdpi.com/2077-0383/9/4/1241Dupilumabatopic dermatitisbiologicalsconjunctivitisrosacea-like folliculitis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tamara Quint Patrick M. Brunner Christoph Sinz Irene Steiner Robin Ristl Kornelia Vigl Susanne Kimeswenger Katharina Neubauer Detlev Pirkhammer Martin Zikeli Wolfram Hoetzenecker Norbert Reider Christine Bangert |
spellingShingle |
Tamara Quint Patrick M. Brunner Christoph Sinz Irene Steiner Robin Ristl Kornelia Vigl Susanne Kimeswenger Katharina Neubauer Detlev Pirkhammer Martin Zikeli Wolfram Hoetzenecker Norbert Reider Christine Bangert Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis Journal of Clinical Medicine Dupilumab atopic dermatitis biologicals conjunctivitis rosacea-like folliculitis |
author_facet |
Tamara Quint Patrick M. Brunner Christoph Sinz Irene Steiner Robin Ristl Kornelia Vigl Susanne Kimeswenger Katharina Neubauer Detlev Pirkhammer Martin Zikeli Wolfram Hoetzenecker Norbert Reider Christine Bangert |
author_sort |
Tamara Quint |
title |
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_short |
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_full |
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_fullStr |
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_full_unstemmed |
Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis |
title_sort |
dupilumab for the treatment of atopic dermatitis in an austrian cohort-real-life data shows rosacea-like folliculitis |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-04-01 |
description |
Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation. |
topic |
Dupilumab atopic dermatitis biologicals conjunctivitis rosacea-like folliculitis |
url |
https://www.mdpi.com/2077-0383/9/4/1241 |
work_keys_str_mv |
AT tamaraquint dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT patrickmbrunner dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT christophsinz dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT irenesteiner dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT robinristl dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT korneliavigl dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT susannekimeswenger dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT katharinaneubauer dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT detlevpirkhammer dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT martinzikeli dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT wolframhoetzenecker dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT norbertreider dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis AT christinebangert dupilumabforthetreatmentofatopicdermatitisinanaustriancohortreallifedatashowsrosacealikefolliculitis |
_version_ |
1724647485284024320 |